Moderate Pain - Pipeline Review, H2 2013

Moderate Pain – Pipeline Review, H2 2013

Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on [email protected] with (Moderate Pain – Pipeline Review Market) in subject line and your contact details.

Moderate Pain – Pipeline Review, H2 2013, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Moderate Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Moderate Pain. Moderate Pain – Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope of the Report

- A snapshot of the global therapeutic scenario for Moderate Pain.
- A review of the Moderate Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Moderate Pain pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Complete report is spread across 64 pages is available @ http://www.reportsnreports.com/reports/271743-moderate-pain-pipeline-review-h2-2013.html.

Reasons to Buy the Report Moderate Pain – Pipeline Review, H2 2013

- Identify and understand important and diverse types of therapeutics under development for Moderate Pain.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Moderate Pain pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Buy a copy of report @ http://www.reportsnreports.com/purchase.aspx?name=271743.

List of Tables
Number of Products Under Development for Moderate Pain, H2 2013 8
Products under Development for Moderate Pain – Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 11
Comparative Analysis by Late Stage Development, H2 2013 12
Comparative Analysis by Mid Clinical Stage Development, H2 2013 13
Comparative Analysis by Early Clinical Stage Development, H2 2013 14
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 15
Products under Development by Companies, H2 2013 16
Nektar Therapeutics, H2 2013 17
Esteve Group, H2 2013 18
Pain Therapeutics, Inc., H2 2013 19
Pfizer Inc., H2 2013 20
Menarini Group, H2 2013 21
Acura Pharmaceuticals, Inc., H2 2013 22
Elite Pharmaceuticals, Inc., H2 2013 23
Charleston Laboratories, Inc., H2 2013 24
Trevena, Inc., H2 2013 25
QRxPharma Limited, H2 2013 26
KemPharm, Inc., H2 2013 27
TheraQuest Biosciences, LLC, H2 2013 28
Assessment by Monotherapy Products, H2 2013 29
Assessment by Combination Products, H2 2013 30
Assessment by Stage and Route of Administration, H2 2013 32
Assessment by Stage and Molecule Type, H2 2013 34
Moderate Pain Therapeutics – Drug Profile Updates 54
Moderate Pain Therapeutics – Discontinued Products 58
Moderate Pain Therapeutics – Dormant Products 59

Inquiry Before Buying @ http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=271743

List of Figures
Number of Products under Development for Moderate Pain, H2 2013 8
Products under Development for Moderate Pain – Comparative Analysis, H2 2013 9
Products under Development by Companies, H2 2013 10

Late Stage Products, H2 2013 12
Mid Clinical Stage Products, H2 2013 13
Early Clinical Stage Products, H2 2013 14
Pre-Clinical Stage Products, H2 2013 15
Assessment by Monotherapy Products, H2 2013 29
Assessment by Combination Products, H2 2013 30
Assessment by Route of Administration, H2 2013 31
Assessment by Stage and Route of Administration, H2 2013 32
Assessment by Molecule Type, H2 2013 33
Assessment by Stage and Molecule Type, H2 2013 34

Inquire for Discount @ http://www.reportsnreports.com/contacts/discount.aspx?name=271743.

Explore Report on Pharmaceuticals Market.

Contact [email protected] / Call +1 888 391 5441 for further information on “Moderate Pain – Pipeline Review, H2 2013” report OR for any other market research and intelligence needs you may have for your business.